Biosun Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biosun Pharma - overview
Established
2020
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Founded in 2020 and based in Hangzhou, China, Biosun Pharma operates as a biomedical technology company that provides molecular targeting and antibody drugs for tumors, autoimmune diseases and inflammatory diseases. The company has clinical operations branches in Hangzhou, Chengdu, Changsha, and Zhengzhou. In October 2023, it closed series B+ funding from Sinowisdom. In May 2025, Biosun Pharma closed a series C+ from new investors Hyfinity Investments and Zhejiang Yuhang Industrial Transformation & Upgrading Investment.
The company engages in the development of drugs for tumors, autoimmune diseases, and inflammatory diseases. Its product Bangsairuini completed the phase III clinical study. Products applicable to myeloproliferative neoplasms, lymphomas and other blood diseases. Besides, it is developing Bangsatini for autoimmune diseases, such as immune thrombocytopenia (ITP), chronic immune urticaria, and chronic graft-versus-host diseases.
The company generates revenue by doing research, development and providing molecular targeted and antibody drugs.
Current Investors
Shenzhen Capital Real Estate Fund, ZJKF Capital Management, Puhua Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.biosunpharma.cn
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.